SLC5A2 and heart failure: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral antidiabetic drugs that have been shown to reduce the risk of worsening heart failure or cardiovascular death in patients with HFrEF (10, 11).